Submission of Matters to a Vote of Security Holders

SEC Form 8-K Summary

Registrant: Galecto, Inc. (Nasdaq: GLTO). The request metadata identifies Damora Therapeutics, Inc., but the filing names Galecto, Inc. as the registrant.

Business Context and Reporting Period

This Form 8-K reports the results of Galecto’s annual meeting of stockholders held on May 26, 2021. The report was signed and filed on May 28, 2021. It is not a quarterly or annual financial-results filing.

Financial and Operating Metrics

  • The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating-performance metrics.
  • Common shares entitled to vote: 25,261,832.
  • Shares present or represented by valid proxy: 18,501,631.

Material Changes Versus Prior Comparable Period

The filing does not report financial or operating changes versus a prior period. It records stockholder voting outcomes and board composition.

Meeting Results, Outlook, and Other Matters

  • Chau Q. Khuong, Søren Møller, Ph.D., and Anne Prener, M.D. were elected as Class I directors to serve until the 2024 annual meeting, subject to earlier departure.
  • Votes for and withheld were: Chau Q. Khuong, 16,613,203 and 693,996; Søren Møller, Ph.D., 16,577,251 and 729,948; and Anne Prener, M.D., 17,247,194 and 60,005, respectively.
  • There were 1,194,432 broker non-votes on the director election.
  • Stockholders ratified EY Godkendt Revisionspartnerselskab as the independent registered public accounting firm for the fiscal year ending December 31, 2021.
  • The auditor ratification vote was 18,489,070 for, 11,340 against, and 1,221 abstentions, with no broker non-votes.
  • The filing contains no management guidance, business outlook, material contingencies, or unusual financial items.

Important Facts to Verify

  • Confirm the issuer identity, because the supplied metadata names Damora Therapeutics, Inc., while the filing identifies Galecto, Inc. and ticker GLTO.
  • Verify the elected directors’ service terms and any subsequent changes to the board.
  • Verify EY Godkendt Revisionspartnerselskab’s appointment and any later auditor change for fiscal 2021.
  • Review the April 14, 2021 proxy statement for additional proposal details and voting information.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.